Neurology
Stiff-Person Syndrome
2
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Stiff-Person syndrome is an early-stage landscape with 2 programs across 3 companies. The most active players are Kyverna Therapeutics, Roche, Akero Therapeutics. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 21
Phase 3
No programs
Approved1
Analysis
Modality Breakdown
4programs
Small molecule250%
Monoclonal antibody125%
Cell therapy125%
Modality classified for 100% of 4 pipeline programs.
Analysis
Trial Status
5
clinical trials
Withdrawn1 · 20%
Unknown status1 · 20%
Not yet recruiting1 · 20%
Completed1 · 20%
Active, not recruiting1 · 20%
Clinical Trials
Trial Activity
Rituximab to Treat Stiff Person Syndrome
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00091897·24 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)